Close Menu

NEW YORK (GenomeWeb) – NeoGenomics today announced a definitive agreement to acquire clinical oncology laboratory Genoptix for $125 million in cash and 1 million shares of NeoGenomics' stock.

Based in Carlsbad, California, Genoptix specializes on hematology and solid tumor testing, and has well-established relationships with community oncology practices, a market that has not been served well with NeoGenomics' capabilities in next-generation sequencing and liquid biopsy, the company said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Feb
23
Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Feb
24
Sponsored by
SCHOTT MINIFAB

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints.